The neurodevelopmental assessment crisis is not primarily a funding problem. It is a system design problem. Specialist clinician time is the scarcest resource in the pathway — and today, far too much of it is consumed by structured history-taking that could be done before the appointment begins. A consultant psychiatrist or clinical psychologist spending the first 40 minutes of a consultation gathering information that the patient has answered many times before is a systemic inefficiency that costs UK health systems millions, costs global health systems billions, and costs patients years.
Allo Clinical is being developed to address this directly. It is an AI-powered neurodevelopmental assessment support tool — built to be used before the clinical consultation — that collates, structures, and synthesises the patient's functional profile across multiple neurodevelopmental domains. By the time the clinician opens the consultation, they have in front of them a comprehensive, evidence-based profile rather than a blank page. What previously required multiple appointments can begin with the depth and breadth of a structured pre-assessment already complete.
Addressing the biases that have hidden millions from diagnosis
The science of neurodevelopmental under-diagnosis is well-established. Women are diagnosed with ADHD on average seven years later than men. ASD is identified in boys at four times the rate of girls — not because it is rarer, but because the behavioural presentations differ and the tools were validated predominantly on male populations. Cultural and socioeconomic factors create further diagnostic shadows. Allo Clinical is being engineered from the ground up to detect and correct for these biases — not as an afterthought, but as a core design principle.
The platform incorporates proprietary correction methodology — developed by a practising UK clinician with deep expertise in neurodevelopmental under-diagnosis — that adjusts for the masking behaviours, internalised presentations, and cultural factors that cause standard assessment tools to miss the patients who need help most. The precise mechanism of this correction is protected intellectual property. What we can say is that it is grounded in the peer-reviewed masking literature and validated against real-world diagnostic data.
Beyond bias correction, Allo Clinical integrates established, clinically validated assessment instruments — the same tools used by specialist clinicians in UK and global private practice — synthesising multi-source data in a way that no single tool has previously achieved in one consultation-ready package.
Clinical safety is not a feature — it is the foundation
Allo Clinical is being built to MHRA Software as a Medical Device standards from day one. The clinical safety architecture — designed by the same DCB0129-qualified physician who leads SDHA — includes multi-tier safety classification, mandatory clinician review gates, and a regulatory compliance layer that means every output is designed to support, never to replace, the diagnosing clinician's professional judgement. This is not an app that tells people they have ADHD. It is a clinical instrument that gives the clinician more to work with in the time they have.
